Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…cluded patients who received at least one ICI (e.g., nivolumab, pembrolizumab); Cohort 2 included those who did not. Propensity score matchin…
… TNBC (ER-/PR-/HER2-) who received at least one dose of an ICI (pembrolizumab, atezolizumab, nivolumab, or durvalumab) between 2014 and 2025.…
…on E, Sondak VK, Ribas A. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023 Mar 2;388(9):813-823.B…
…(42.6%) did not. The most frequently administered regimens were ipilimumab, nivolumab, and pembrolizumab, with or without platinum-based c…
…in J; CheckMate 067 Investigators. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1)…
…ipilimumab/chemotherapy), against KEYNOTE-189, and KEYNOTE-407 (pembrolizumab/chemotherapy). We analyzed both the progression free survival (…
…or the treatment of OX40+ sarcoma and other solid tumors, where HX111 could potentially be a candidate treatment, warranting further …
…berman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023 …
…n = 4, other/unknown primary n = 17) from patients treated with ipilimumab 3mg/kg and nivolumab 1mg/kg at Thomas Jefferson University were…
…combination with the immune checkpoint inhibitors nivolumab and ipilimumab. We analyzed PBMCs from a subset of patients who demonstrated a…
…nt with anal cancer previously treated with 5 agents, including nivolumab. The duration of the complete responses is 8 months and 9 month…